Regn2477+regn1033 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 15 | Inclusion body myositis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03710941 (ClinicalTrials.gov) | February 19, 2019 | 15/10/2018 | Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis | Sporadic Inclusion Body Myositis | Drug: REGN2477+REGN1033;Drug: Matching placebo | Regeneron Pharmaceuticals | NULL | Withdrawn | 45 Years | 75 Years | All | 0 | Phase 2 | NULL |